16 December 2014
Boston Strategics Enters into an Innovative Risk-Sharing Agreement with the MD Anderson Cancer Center to Conduct a Phase 1/2a Clinical Trial of E6201 in Patients with Advanced Hematologic Malignancies Including Acute Myeloid Leukemia
BOSTON–(BUSINESS WIRE)–Boston Strategics Corporation (BSC), an integrated clinical-stage drug research and development (R&D) company, Boston, MA, today announced that it has entered into a risk-sharing agreement with the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a Phase 1/2a clinical trial of E6201 in patients with advanced hematologic malignancies, including acute myeloid leukemia (AML).
Working in collaboration with MD Anderson, BSC will undertake this clinical Proof of Concept (PoC) trial of E6201, a dual-targeted FLT3 and MEK inhibitor for the high unmet need of FLT3 mutated AML. The trial is supported by recent translational data generated by Gautam Borthakur, MD, Michael Andreef, MD, PhD and colleagues in the Leukemia Department at MD Anderson. Dr. Borthakur will serve as Principal Investigator on the clinical trial.
Under this innovative agreement, MD Anderson commits its own resources to conduct the clinical study, while BSC provides the drug supply, study execution, safety monitoring, and data management. Both organizations will share the development challenges and risks for these high unmet need patients with advanced hematologic malignancies who need effective and new treatments.
This collaboration is a further step toward the realization of BSC’s “True” Open Innovation™ platform to develop drug candidates with potential to significantly improve patients’ health care. The BSC approach invites innovative clinical academic centers, such as MD Anderson, to participate more broadly in the clinical development process in an effort to share the risk and trial outcomes. The flexibility and collaborative approach of “True” Open Innovation™ empower centers like MD Anderson to become entrepreneurial partners together with BSC and the other members of its global network.
“We are very excited and pleased to work with MD Anderson, a leading cancer health care institution in which we share our core values of innovative patient-centered and science-based approaches,” says Keizo Koya, Ph.D., CEO of Boston Strategics. “This is a historical milestone for BSC to build on our concept of “True” Open Innovation™ by collaborating with such an institution as MD Anderson to create a new effective treatment for AML patients.”
“Our mission is to bring novel drugs to patients. Unfortunately there are drugs that, despite its promise, struggle to progress through clinical development. To bring those drugs to patients and unlock their full potential, we are firmly committed to working with the oncology community and to devise novel and creative business structures that make those collaborations possible“ says Ferran Prat, Ph.D., VP MD Anderson Cancer Center.
About Boston Strategics Corporation (BSC):
BSC is an integrated drug R&D company with experience in developing, managing and optimizing global drug development programs from late discovery, through translational research, first-in-man or proof-of-concept clinical studies. Its mission is to continuously improve patient health care by changing the drug R&D paradigm using “True” Open Innovation™ platform.
About “True” Open Innovation™ :
“True” Open Innovation™ is a revolutionary business concept that breaks through internal infrastructure limitations by drawing on the Boston Strategics core team of experts and introducing additional external, key expertise in a given area. In a highly specialized industry such as drug development, the limitation of large, internal organizations and the expertise of the internal team members is critical. “True” Open Innovation overcomes such limitations by reducing the need for large infrastructure, and draws on additional critical drug development expertise, based on the unique needs of a particular program. In summary Boston Strategics utilizes its own global core competencies coupled with external Strategic Global Outsourcing as needed.